BioNTech Co-Founders to Exit in 2026 as 2025 Revenues Hit €2.87 Billion
BioNTech posted 2025 revenues of €2.87 billion with an IFRS net loss of €1.14 billion (adjusted loss €117 million) and held €17.2 billion in cash and securities. Co-founders Ugur Sahin and Özlem Türeci will exit end-2026 to start a next-gen mRNA company, while six late-stage data readouts are slated for 2026.
1. Financial Results and Outlook
For the year ended December 31, 2025, BioNTech generated revenues of €2,869.9 million and reported an IFRS net loss of €1,136.1 million (adjusted net loss €117.1 million), compared with revenues of €2,751.1 million and a net loss of €665.3 million in 2024. The company closed 2025 with €17.2 billion in cash, cash equivalents and security investments and issued guidance for 2026 revenues of €2.0–2.3 billion, adjusted R&D expenses of €2.2–2.5 billion and adjusted SG&A expenses of €700–800 million.
2. Pipeline and Trial Updates
BioNTech plans six late-stage data readouts in 2026 across its immunomodulator, antibody-drug conjugate and mRNA cancer immunotherapy programs. The company expects eight global Phase 3 trials for its PD-L1/VEGF-A bispecific immunomodulator pumitamig, in collaboration with Bristol Myers Squibb, to be ongoing by year-end.
3. Founder Departure and Corporate Transition
Co-founders Ugur Sahin and Özlem Türeci will depart by end-2026 to establish an independent company focused on next-generation mRNA innovations. BioNTech’s management transition is planned to conclude by the end of 2026, signaling a shift in leadership amid ongoing pipeline advancement.